Emergent BioSolutions Inc. EBS · NYSE
$6.24 +0.16% (+$0.01)
Summary
36 / 100 · Bulios Score
What speaks for it
- It bought back its own shares for $24.9M in the last fiscal year, 7.8% of its market value.
- Out of every 100 USD of revenue, 11 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 13% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 14% a year over 5 years. Over the last 3 years it fell by 13% a year.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $176.8M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 3
- Sell 1
Today's price within the analysts' price targets
The average target of $10 is 60% above today's price. 73% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 95%
- Contracts and Grants 5.1%
By region
- UNITED STATES 71%
- Other Geographical Area 18%
- CANADA 10%
Product brings in 95% of revenue.
Segments in detail